9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 901–1,000 of 1,000
Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones
Cice, G. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf019 · Cited by 3
Cowart, K., White, R. T., Olson, K., Carris, N. W., Hanna, K., & Zgibor, J. C. (2025) · JMIR Research Protocols · doi:10.2196/67014 · Cited by 4
Soriano, L. C., Moreno-Lostao, A., Calonge, M., Rivas, A., Pulido, J., Colchero, M. C., Artola, S., Serrano, R., Franch‐Nadal, J., & Regidor, E. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106069 · Cited by 3
“Therefore, the results cannot be extrapolated to the clinical practice of all primary care physicians in Spain.”
The New Modern Medicine: Disease, Evidence, and Epidemiological Medicine
Fuller, J. (2025) · doi:10.1093/9780190066178.001.0001 · Cited by 7
Vaccaro, O., Masulli, M., & Riccardi, G. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.04.008 · Cited by 3
Statement for Diabetes Guideline Has Been on Discussion for Future Better Lives
Bando, H. (2018) · Journal of Endocrinology and Thyroid Research · doi:10.19080/jetr.2018.03.555616 · Cited by 3
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
Part Four: Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications
Meyer, K. S., Roberts, J., & Croley, K. S. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.310 · Cited by 3
Basile, G. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.2.5 · Cited by 3
Gopalan, A., Winn, A. N., Karter, A. J., & Laiteerapong, N. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07746-4 · Cited by 3
Wettergreen, S. A., Stewart, M. P., Kennedy, K., & Trujillo, J. M. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0108 · Cited by 3
The Situation Among Egyptian Elderly with Type 2 Diabetes; A Call for Action
Ghazi, H. A. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.259116 · Cited by 4
Liu, Y., Yan, S., Liu, J., Liu, H., Song, L., Yao, X., Jiang, J., Li, F., Du, K., Liu, D., et al. (2023) · Biomedical Chromatography · doi:10.1002/bmc.5607 · Cited by 3
Almodóvar, A. S., & Nahata, M. C. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043613 · Cited by 3
Edwards, S., Lam, C., & Thomas, L. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.276 · Cited by 3
Jammah, A. A., Roushdy, N., Gamil, M., Diab, N. A., Abdelmonaem, N., Safarini, S., Gadallah, M., Zaid, N. A., Shihadeh, Y., Saeed, M., et al. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100164 · Cited by 3
Basu, A., Montano‐Campos, F., Huang, E. S., Laiteerapong, N., & Barthold, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15878 · Cited by 3
“11 Necessary switching to appropriate glucose-lowering drugs for primary versus secondary prevention of CVD remains understudied.”
Shen, S., Di, X., Xiang, L., Li, H., & Liao, B. (2024) · Translational Andrology and Urology · doi:10.21037/tau-24-212 · Cited by 3
Gentile, S., Strollo, F., Guarino, G., Ronchi, A., Satta, E., Corte, T. D., Fulgione, E., Babino, G., Mattera, E., Martedì, E., et al. (2024) · Diabetology · doi:10.3390/diabetology5070053 · Cited by 3
Nugroho, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303350851241021105850 · Cited by 4
Wathani, I. H. N., Purba, M. B., & Helmyati, S. (2024) · Jurnal Gizi Klinik Indonesia · doi:10.22146/ijcn.91474 · Cited by 3
“Obat hipoglikemik oral golongan sulfonilurea, tiazolidinedion, dan meglitid dapat memberikan efek pada kenaikan berat bedan sedangkan golongan biguanid dan penghambat SGLT-2 memberikan efek penurunan berat badan darah [25,44].”
Wang, A. C., Bitzas, S., Perez, D., Schwartz, J. A., Zaidi, S., Oster, J., & Bergese, S. D. (2025) · Life · doi:10.3390/life15030427 · Cited by 4
“Not only does SGLT2is significantly lower HbA1c and fasting plasma glucose for T2DM patients, especially those at high risk for ASCVD, HF, and/or CKD, it also promotes weight loss and a reduction in high blood pressure [39,40].”
Development of a patient decision aid for type 2 diabetes mellitus: a patient-centered approach
Tichler, A., Hertroijs, D. F. L., Ruwaard, D., Brouwers, M. C. G. J., & Elissen, A. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02772-7 · Cited by 4
Yoon, S., Lau, R., Kwan, Y. H., Liu, H., Sahrin, R., Phang, J. K., Zhang, Y., Graves, N., & Low, L. L. (2025) · Digital Health · doi:10.1177/20552076251322654 · Cited by 7
Carretero-Anibarro, E., López-Tello, A. M., Hamud-Uedha, M., & Roldan-Reguera, B. (2020) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.11.011 · Cited by 3
Bedoya‐Joaqui, V., Gómez, N. B., Ortiz, R. C., Osorio-Toro, L. M., Muñoz-Lombo, J. P., Cifuentes, C. A. S., García, M. A. M., & Abreu-Lomba, A. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000319 · Cited by 5
Clements, J. N. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001248 · Cited by 3
Long, T., Lin, J.-T., Lin, M.-H., Wu, Q.-L., Lai, J.-M., Li, S.-Z., Zhou, Z.-C., Zeng, J.-Y., Huang, J.-S., Zeng, C.-P., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0692 · Cited by 3
Ferreira‐Hermosillo, A., & Elías-López, D. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000013 · Cited by 7
Diabetes: how to manage cardiovascular risk in secondary prevention patients
Anderson, S. L., & Marrs, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-10-1 · Cited by 3
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.03.011 · Cited by 3
Cin, A., & Hıntıstan, S. (2022) · Turkish Journal of Diabetes Nursing · doi:10.29228/tjdn.58093 · Cited by 3
McCrimmon, R. J., Home, P., CHENG, A. Y. Y., Giorgino, F., Fonseca, V. A., Souhami, E., Alvarez, A., Picard, P., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14825 · Cited by 3
Alhaj, O., & Afandi, B. O. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1755440 · Cited by 3
Treating type 2 diabetes: moving towards precision medicine
Yu, O. H. Y., & Shin, J. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00197-2 · Cited by 3
Prediabetes, Atrial Fibrillation, and Heart Failure: An Intersection of Comorbidities
Hoogwerf, B. J. (2022) · Diabetes Care · doi:10.2337/dci22-0042 · Cited by 3
Factors Associated with Risk of Diabulimia in Greek Adult Population with Type 1 Diabetes Mellitus
Apergi, K., Romanidou, M., Abdelkhalek, H., & Gonidakis, F. (2023) · Dietetics · doi:10.3390/dietetics2010003 · Cited by 3
“An individualized healthy eating pattern, along with regular physical activity and proper insulin therapy, has been proven to be the key components of T1DM management for the prevention or delay of diabetes complications [2,3].”
BackgroundErukainure, O. L., Salau, V. F., Olofinsan, K. A., Chukwuma, C. I., Osagie, A. O., Ebuehi, O. A. T., & Islam, M. S. (2023) · Nutrire · doi:10.1186/s41110-022-00187-3 · Cited by 3
Estimating a Personalized Basal Insulin Dose from Short-Term Closed-Loop Data in Type 2 Diabetes
Engell, S. E., Aradóttir, T. B., Ritschel, T. K. S., Bengtsson, H. L., & Jørgensen, J. B. (2022) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc51059.2022.9992960 · Cited by 4
Robles, N. R., Álvarez, Á., & Fıcı, F. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.024 · Cited by 3
The Nuances Surrounding Insulin Prescribing
McKee, A. M., Yancey, A. M., Zhang, R. M., & McGill, J. B. (2023) · Clinical Diabetes · doi:10.2337/cd22-0117 · Cited by 3
Franck, L., Donovan, A., Kellison, M., & McAdam‐Marx, C. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.04.007 · Cited by 3
Horii, T., Otsuka, M., & Yasu, T. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003177 · Cited by 3
Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach
Wong, E., & Nguyen, T. V. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.233 · Cited by 5
Взаємозв’язок цукрового діабету і захворювань тканин пародонта
Dobrovynska, O. V., Khlyebas, S. V., Мазур, І. П., & Slobodianyk-Kolomoyets, M. V. (2023) · Oral and General Health · doi:10.22141/ogh.4.1.2023.148 · Cited by 3
Ding, Q., Spatz, E. S., Bena, J., Morrison, S. L., Levay, M., Lin, H., Grey, M. J., Edwards, N. E., Isaacs, D. M., West, L. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029058 · Cited by 4
Prevalence of Erectile Dysfunction in Men with Type 2 Diabetes Mellitus in Osun State, Nigeria
Airaodion, A. I., Ijioma, C. E., Ejikem, P. I., Abali, I. O., Aminu-Ayinde, O. E., Ogwu, C. I., Kalesanwo, E. A., Amuta, A. C., Areh, J. E., Odarah, J. E., et al. (2023) · Direct Research Journal of Health and Pharmacology · doi:10.26765/drjhp20198426375 · Cited by 6
Prevalence and patterns of catastrophic spending for antidiabetic medication in 2020
Devine, J. W., Lim, D., Lugo, A. M., & Farley, J. F. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.10.1158 · Cited by 4
Ponomareva, E., Schmerold, L. M., Srinivas, S. S. S., Preblick, R., Park, S., Wilson, L., & Revel, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277058 · Cited by 3
“BI analogs demonstrate a relatively flatter, more prolonged, and consistent pharmacokinetic and pharmacodynamic profile compared to neutral protamine Hagedorn (NPH) insulin 19 .”
BackgroundGerber, A., Fischetti, B., Popova, O., & Longo, M. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225231221059 · Cited by 3
Khan, M. F., Jamil, B., & Senneville, É. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00012-7 · Cited by 4
Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus
Kang, S., Ahn, Y., Oh, T. K., Lee, W., Chun, S. W., Bae, B., Dahaoui, A., Jeong, J. S., Jung, S.-E., & Jang, H. C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0297 · Cited by 3
“When uncontrolled with basal insulin, the addition of prandial insulin or switching to premix insulin can be a feasible option of insulin intensification in routine clinical practices [4,5].”
BackgroundZheng, M., Begum, M., Bernardo, C., Stocks, N. P., & González‐Chica, D. A. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.03.001 · Cited by 3
Liu, W., Gao, Y., Zhang, R., Gong, S., Wang, X., Wang, Y., Cai, X., Zhang, X., Xie, X., Han, X., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03820-5 · Cited by 3
Chen, Q., Yu, C., Wu, Q., Song, R., Liu, Y., Feng, S., Yu, C., & Jia, J. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s433377 · Cited by 3
Molaee, M. C., Gharibnaseri, Z., & Karami, M. A. (2024) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101002 · Cited by 4
Incretin therapy in feline diabetes mellitus – A review of the current state of research
Haller, N., & Lutz, T. A. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106869 · Cited by 4
IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
Seetharaman, R., Monteiro, R. C., Maradia, J., & Tripathi, R. K. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0058 · Cited by 4
SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety
Kułak, K. B., Chamera-Cyrek, K., Janik, I., Kuśmierska, M., Koman, A. M., Pliszka, M., Gadżała, K., Palacz, K. A., Sztybór, I., & Przygodzka, S. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.52083 · Cited by 3
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Price, J. E., Fujihara, K., Kodama, S., Yamazaki, K., Maegawa, H., Yamazaki, T., & Sone, H. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103168 · Cited by 4
Aydemir, S., Aydın, S. Ş., Aksakal, E., Altınkaya, O., Özmen, M., & Birdal, O. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04454-1 · Cited by 3
O’Reilly, E. A., Cross, L. V., Hayes, J. S., & Kubiak, N. T. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.04.009 · Cited by 3
Exploring mobile health applications for self-management of Diabetes Mellitus
Bellei, E. A., Lisboa, H. R. K., & Marchi, A. C. B. D. (2020) · doi:10.5753/sbcas.2020.11560 · Cited by 4
Cescon, M., Deshpande, S., Doyle, F., & Dassau, E. (2019) · American Control Conference · doi:10.23919/acc.2019.8814817 · Cited by 4
Sánchez‐Rey, B. S., Sanz, M., Ramos, P. M., Gilabert, N., da Costa, R. J. S., Otero-Rodríguez, S., Carles, P., Ruano, P., & Quiroga, B. (2020) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2020.06.004 · Cited by 3
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Gomes, G. J. N., Sartori, G. L., Sampaio, A. M., Pereira, L. M. V., Ueta, J. M., & de Oliveira, R. E. M. (2021) · Saúde em Redes · doi:10.18310/2446-4813.2021v7n1p217-227 · Cited by 5
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., Rosenblum, N. D., Rosenblum, N. D., Cefalu, W. T., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.126 · Cited by 10
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
Nissaisorakarn, P., Pavlakis, M., & Aala, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.03.001 · Cited by 3
Singh, A. K., & Shah, V. N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0037 · Cited by 3
Tapia-Rivera, J. C., Mendoza-Jaramillo, H. E., González-Villaseñor, C. O., Ramírez-Flores, M., Aguilar‐Velázquez, J. A., López-Quintero, A., Pérez-Guerrero, E. E., Vargas-Rodriguez, M. D. L. Á., Gutiérrez-Hurtado, I. A., & Martínez‐López, E. (2023) · Viruses · doi:10.3390/v15071514 · Cited by 3
Improving Equity in Medication Use through Better Kidney Function Measurement
Tuot, D. S. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020060880 · Cited by 3
Escalada, J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01281-5 · Cited by 3
Shahid, M., Azfaralariff, A., Govender, N., Zubair, M., Najm, A. A., Khan, N. H., Law, D. S. N., & Fazry, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1870035/v1 · Cited by 3
Hung, C.-H., Yen, F., & Wei, J. (2022) · Diabetes Care · doi:10.2337/dc22-0701 · Cited by 2
Qureshy, K., Kirk, A. R., Wolden, M. L., Zonoozi, A. A. M., & Liu, A. (2022) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000260 · Cited by 2
Tan, M. S., Kim, K., Olsen, C. J., & Brixner, D. I. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100127 · Cited by 3
Tye, S. C., Oshima, M., Arnott, C. G., Neuen, B. L., Fletcher, R. A., Neal, B. C., & Heerspink, H. J. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15018 · Cited by 3
Non-albuminuric chronic kidney disease in diabetes
Borg, R., & Persson, F. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1018_22 · Cited by 2
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2023) · Nefrología · doi:10.1016/j.nefro.2023.06.010 · Cited by 2
TIRZEPATIDA - UMA NOVA FARMACOTERAPIA PARA DIABETES MELITTUS TIPO 2
Fontes, L. B. A., & Souza, G. L. D. (2024) · Revista Científica Fagoc. · doi:10.61224/2525-5045.2023.1097 · Cited by 3
Hinojo, C., Cantos, B., Antolín, S., Arqueros, C., Díaz-Redondo, T., González, I., Llabrés, E., Ramírez, J. A., Barral, M., Escudero, M., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.016 · Cited by 2
Social Determinants of Health and Newer Diabetes Medications: NHANES Analysis
Tan, A. K., & Strauss, S. M. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105287 · Cited by 2
Haff, N., Horn, D. M., Bhatkhande, G., Sung, M., Colling, C., Wood, W., Robertson, T., Gaposchkin, D. P., Simmons, L. H., Yang, J., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.007 · Cited by 2
Starke, P., Thürmann, P., Grobe, T., Friede, T., & Mathes, T. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01218-0 · Cited by 2
“…in favor of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) has grown, leading to their adoption as the preferred [7] add-on therapy to metformin for patients with high cardiovascular risk in current clinical practice guidelines [4, 8, 9].”
The impact of epigenetic factors in type 2 diabetes: Insights into development and pathogenesis
Thammanna Gowda, S. S., Rangappa, S., & Hanumesh, P. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100635 · Cited by 3
Hatano, M., Sasabuchi, Y., Okada, A., Ishikura, H., Tanaka, T., Saito, T., Tanaka, S., & Yasunaga, H. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf132 · Cited by 3
“10 14 The weight-reducing action of SGLT-2is may decrease the mechanical load on weight-bearing joints, thereby potentially lowering the risk of osteoarthritis.”
Caturano, A., Galiero, R., Simeon, V., Acierno, C., Nilo, D., Marrone, A., Trotta, M. C., Vetrano, E., Sardu, C., Russo, V., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104284 · Cited by 2
Grigore, M., Grigore, A.-M., Ruxandra-Elena, M.-G., Verde, I., Uscoiu, G., Nicolae, C., Balahura, A.-M., & Ilieşiu, A. (2025) · Life · doi:10.3390/life16010016 · Cited by 3
“…could influence atrial remodeling by reducing EAT and associated inflammatory signaling, by lowering circulating concentrations of advanced glycation end products and profibrotic markers, and by improving intracellular calcium handling, a critical determinant of atrial electrical stability [65,66].”
Bharati, D., Pualsa, D., Mayekar, S., Nadar, J., Mohite, P. B., Kumar, A. A. A. A., & Singh, S. K. (2026) · Life · doi:10.3390/life16020246 · Cited by 2
“However, their long-term use is often associated with limitations such as gastrointestinal side effects, weight gain, hypoglycemia, and inadequate control of oxidative stress and lipid abnormalities [10,11].”
Barakat, G. M., Hassan, S. E. H., Akhdar, H., Duong-Trung, N., & Ramadan, W. (2026) · JMIR AI · doi:10.2196/86960 · Cited by 2
“Thus, the advance in efficacy with semaglutide has been largely achieved through tolerability and monitoring trade-offs and not through an increase in the severity of side effects [15].”
InfluentialWang, C.-H., Chang, W.-C., Chen, H.-Y., Chen, P., Lin, M. H., & Lee, C.-H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02151-x · Cited by 2
Kondeti, P., Chakrabarti, A., Drexler, Y. R., Mesa, R. A., Tremblay, J. O., Gallo, L. C., Lash, J. P., Rosas, S. E., Franceschini, N., Massera, D., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001088 · Cited by 2
Barengolts, E. I., Akbar, A., Layden, B. T., Eisenberg, Y., Priyadarshini, M., Borgia, J. A., Fhied, C. L., Dugas, L. R., & Salim, M. (2020) · Biomedicines · doi:10.3390/biomedicines8110520 · Cited by 2
Halimi, S. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.12.005 · Cited by 2
Laichuthai, N., & DeFronzo, R. A. (2021) · Journal of Endocrinological Science · doi:10.29245/2767-5157/2021/1.1115 · Cited by 3
Lau, D., Eurich, D. T., & Simpson, S. H. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.006 · Cited by 2
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.